Navigation Links
SemBioSys updates Apo AI development program
Date:8/22/2007

TSX symbol: SBS - Canadian Biotechnology Company confirms commercial expression levels of

Apo AI Milano variant and clarifies status of native Apo AI -

CALGARY, Aug. 22 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today updated a release issued on July 12, 2007 announcing that the Company had achieved commercial levels of apolipoprotein AI (native Apo AI) and apolipoprotein AI(Milano) (Apo AI Milano) accumulation in safflower seed lines. SemBioSys has confirmed in multiple assays that it has developed commercial levels of Apo AI Milano in safflower seed lines. Based on further evaluation of the existing data from native Apo AI safflower seed lines, the Company must clarify that, to date, it has not proven it has achieved commercial levels of native Apo AI accumulation in safflower.

While the assays demonstrate that native Apo AI accumulates in safflower, the commercial level threshold set by SemBioSys of 1% total seed protein expression has not yet been attained. Over the coming months SemBioSys will continue to analyze the additional safflower seed lines it currently has in development. The Company expects that the analysis of these seed lines will be complete by the end of the fourth quarter of 2007.

"While this is a setback to our native Apo AI program, we believe it is temporary in nature. Our success with the Milano variant has given us confidence that similar accumulation levels will be found among the remaining native Apo AI plant lines we have created. We successfully achieved the commercial threshold for Apo AI Milano early in our current series of seed lines. We initially believed we had achieved a similar outcome in an early seed line from the native Apo AI series. We are currently, and will continue, analyzing new seed lines between now and the end of 2007 as they be
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2007 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4

Related biology technology :

1. Merge announces sofware updates, upcoming acquisition
2. Tech Digest: Merge eMed product updates; Renaissance Learning 3rd qtr results
3. Solinus updates MailFoundry anti-spam hardware, switching to Linux
4. Wingra Technologies updates data migration software
5. The let-7 microRNA Family Regulates RAS: Implications for Development and Oncogenesis
6. Rapid Method Development With the BioLogic DuoFlow Chromatography System for the Purification of His-Tagged Proteins
7. A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis
8. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
9. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
10. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
11. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2009)..., NEW YORK, Nov. 18 Reportlinker...s available in its catalogue. ,, Biotechnolog... http://www.reportlinker.com/p0164375/Biotechnolog...source=prnewswire&utm_medium=pr&utm_campai...gy are complex chemical compounds used in a range ...
(Date:11/18/2009)... Promega Corporation and SwitchGear G... DNA-protein interactions. , ...Promega Corporation and SwitchGear Genomics announ...nteractions. Results of a study using the HaloCHIP... demonstrate the ability to correlate DNA binding ...
(Date:11/18/2009)...VT-111 significantly reduces key cardiac enzymes a... presented at American Heart Association 2009 Scie...wire/ - Viron Therapeutics Inc., a biotechnology c...ting protein therapeutics derived from pathogens, ...rial evaluating VT-111 (Serp-1), an anti-inflammat...
(Date:11/18/2009)..., BALTIMORE, Nov. 18 Ch...CSBR), an oncology drug development company with a...ting the development and enhancing the value of on...ng agreement with Yale University and Southern Res...or cancer treatment. Scientists from Yale and Sou...
Breaking Biology Technology:Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 2Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 3Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 4Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 5Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 6Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 7Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 8Promega and SwitchGear Publish Findings from Combined Technologies that Correlate Binding Events and Transcriptional Activity 2Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 2Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 3Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 4Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology 2Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology 3Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology 4
...SEY CITY, New Jersey, October 29, Rosetta Genomics... of microRNA-based diagnostics, announced today it...al Healthcare Conference,taking place November 3-4...ty., About MicroRNA, MicroRNAs (miRNAs) are rece...hat act as master regulators and have the potentia...
.... 29 Osteotech, Inc.,(Nasdaq: OSTE ), a leader i...enerative healing, announced today that it has rec... and Drug Administration ("FDA") for its next,gene...) clearance for this,material as a bone graft subs...spine, pelvis and extremities., Sam Owusu-Akyaw, ...
...Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announ... at the Oppenheimer 19th Annual Healthcare Confere...5:40 a.m. Pacific Time) at the,Waldorf=Astoria Hot...ce,President, Finance and Chief Financial Officer,...y, including its clinical development and discover...
Other Biology Technology:Rosetta Genomics to Present at Oppenheimer's 19th Annual Healthcare Conference 2Rosetta Genomics to Present at Oppenheimer's 19th Annual Healthcare Conference 3Osteotech Receives FDA Clearance for its Next Generation Grafting Material 2Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference 3
(Date:11/20/2009)... ANN ARBOR, Mich.---We,ve all read studies about t...ame thing is true at the molecular level, where am...ble to damage when single than when paired up with...ersity of Michigan, along with colleagues in Belgi...protects single cysteines. The research appears in...
(Date:11/20/2009)..., A key question in the origin of biological mol...ether billions of years ago from simple precursors...searchers in Italy have reconstructed one of the e...ains of RNA from individual subunits using nothing...t RNA was one of the first biological molecules pr...
(Date:11/20/2009)... This release is available in German . , I...ical Investigation , Dr. Stefanie Eyerich and Dr. ... Imperial College London and Istituto Dermopatico ...ing discovery. It represents a milestone on the wa...tory skin diseases such as psoriasis and allergic ...
Breaking Biology News(10 mins):Saving the single cysteine: New antioxidant system found 2Discovery of new type of immune cells regulating inflammation in chronic diseases 2Should noninvasive ventilation be considered a high risk procedure during an epidemic 3F 59338 1Should noninvasive ventilation be considered a high risk procedure during an epidemic 3F 59338 2ADSC 26apos 3Bs Pain Management Reinforcement 59333 1ADSC 26apos 3Bs Pain Management Reinforcement 59333 2Dry Skin and Eczema May Be Reduced with New Toxic Substances Control Act 59328 1Dry Skin and Eczema May Be Reduced with New Toxic Substances Control Act 59328 2
...s, cells in your eye are transmitting information ...ies work just as hard to keep that brain alive. Ev...e body -- depends on an internal process called en...nd information healthy and strong. , It,s an incre...at Weill Medical College of Cornell University in ...
... packaging. How nature wraps and tags genes determ...researchers from Harvard and the Massachusetts Ins...t, most detailed study to date of the protein stru...dings reveal surprising and previously unknown spe...ment of the human body and in diseases such as can...
...t growing older are as,inevitable and obvious as “...lain the precise cause of this usually unwelcome t... site of the journal Science,researchers from Dan...Boston say they have found the cellular cause of g...ignant melanoma, the potentially deadly,skin cance...
Other Biology News:Weill Cornell Research Reveals Secrets Of Trafficking Within Cells 2Weill Cornell Research Reveals Secrets Of Trafficking Within Cells 3Protein Packages Found To Activate Genes; May Be What Regulates Development And Disease 2Protein Packages Found To Activate Genes; May Be What Regulates Development And Disease 3Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery 2Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery 3
Mouse Anti-Human PPP2R2C Monoclonal Antibody, Unconjugated, Clone 6D1 from Novus Biologicals
96-well 0.2 ml PCR Plate Caps, 300 from Bio-Rad
PROTEIN G PLUS AGAROSE from Pierce Biotechnology, Inc.
Mouse Anti-Human ALS2CR8 Polyclonal Antibody, Unconjugated from Novus Biologicals
Biology Products: